Found to inhibit HCV activity by approximately 90%
Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus’ lifecycle.
SBEL1 is a compound isolated from Chinese herbal medicines that was found to inhibit HCV activity by approximately 90%. SBEL1 is extracted from a herb found in certain regions of Taiwan and Southern China. In Chinese medicine, it is used to treat sore throats and inflammations. The function of SBEL1 within the plant is unknown and its role and origins are currently being investigated.
Scientists pre-treated human liver cells in vitro with SBEL1 prior to HCV infection and found that SBEL1 pre-treated cells contained 23 percent less HCV protein than the control, suggesting that SBEL1 blocks virus entry. The liver cells transfected with an HCV internal ribosome entry site (IRES)-driven luciferase reporter that were treated with SBEL1 reduced reporter activity by 50% compared to control. This suggests that that SBEL1 inhibits IRES-mediated translation, a critical process for viral protein production.
In addition, the HCV ribonucleic acid (RNA) levels were significantly reduced by 78 percent in HCV infected cells treated with SBEL1 compared to the control group. This demonstrates that SBEL1 may also affect the viral RNA replication process.
Prof. Markus Peck-Radosavljevic, Secretary-General of the European Association for the Study of the Liver and Associate Professor of Medicine, University of Vienna, Austria, commented: “People infected with hepatitis C are at risk of developing severe liver damage including liver cancer and cirrhosis. In the past, less than 20 percent of all HCV patients were treated because the available treatments were unsuitable due to poor efficacy and high toxicity. Recent advances means that we can now virtually cure HCV without unpleasant side effects. However, the different virus genotypes coupled with the complexity of the disease means there is still a major unmet need to improve options for all populations.”
Professor Peck-Radosavljevic continued: “SBEL1 has demonstrated significant inhibition of HCV at multiple stages of the viral lifecycle, which is an exciting discovery because it allows us to gain a deeper understanding of the virus and its interactions with other compounds. Ultimately this adds to our library of knowledge that may bring us closer to improving future treatment outcomes.”
HCV invades cells in the body by binding to specific receptors on the cell, enabling the virus to enter it.2 Once inside, HCV hijacks functions of the cell known as transcription, translation and replication, which enables HCV to make copies of its viral genome and proteins, allowing the virus to spread to other sites of the body.2 When HCV enters the host cell, it releases viral (+)RNA that is transcribed by viral RNA replicase into viral (-)RNA, which can be used as a template for viral genome replication to produce more (+) RNA or for viral protein synthesis. Once the viral RNA is transcribed, HCV initiates a process known as IRES-mediated translation, which allows the viral RNA to be translated into proteins by bypassing certain protein translation checkpoints that would normally be required by the host cell to start protein translation. Viral RNA is the genetic material that gives HCV its particular characteristics. This process enables the virus to take advantage of the host cell’s protein translation machinery for its own purposes.
There are an estimated 150 million to 200 million people living with chronic HCV and more than 350,000 people die annually from HCV-related diseases. HCV is transmitted through blood contact between an infected individual and someone who is not infected. This can occur through needlestick injuries or sharing of equipment used to inject drugs.
The Latest on: Hepatitis C
[google_news title=”” keyword=”Hepatitis C” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Hepatitis C
- JAMA: Early Treatment with Antivirals Effective in Children with Hepatitis Con April 28, 2024 at 7:00 am
A recent study published in the Journal of American Medical Association unveiled a promising findings regarding the efficacy and cost-effectiveness of early treatment for children with ...
- Tests And Crackdowns On Hepatitis Outbreaks Triggered By Outbreakson April 28, 2024 at 3:29 am
There has been an alarming increase in the number of hepatitis cases in Rawalpindi’s Fauji Colony area. To protect residents from the growing health threat, extensive awareness and testing initiatives ...
- U.S. Lags Behind Other Countries in Hepatitis-C Treatmenton April 28, 2024 at 3:00 am
A Biden initiative languishes without Congressional approval. By Ted Alcorn In the 10 years since the drugmaker Gilead debuted a revolutionary treatment for hepatitis C, a wave of new therapies have ...
- Hepatitis outbreak prompts crackdown, testing driveon April 28, 2024 at 12:44 am
This crackdown is part of a broader effort to enforce cleanliness protocols and mitigate the spread of hepatitis within the community. The prevalence of hepatitis in Fauji Colony has been alarming, ...
- Hepatitis C diagnosis 'like a death sentence'on April 27, 2024 at 12:46 am
A woman who contracted hepatitis C after being given contaminated blood during a transfusion more than 50 years ago says she feels like her life "has been stolen". Hazel Busby, 73, says the ordeal ...
- Canada Will Likely Miss WHO's Hepatitis C Elimination Targeton April 25, 2024 at 3:35 am
Canada is unlikely to meet the World Health Organization's (WHO's) target of eliminating the hepatitis C virus ( HCV) by 2030, research suggested. The elimination targets for HCV include an 80% ...
- Hepatitis Kills 3500 People Each Day, Says WHOon April 24, 2024 at 7:28 pm
Although annual incidence decreased from 2.5 million in 2019 to 2.2 million in 2022, the WHO considers it to be high.
- Global Hepatitis C Virus (HCV) Testing Industryon April 22, 2024 at 12:13 pm
The Global Hepatitis C Virus (HCV) Testing Industry is on a promising growth trajectory, fueled by increasing awareness and improved diagnostic tools. According to industry estimates, the market ...
- Canada's Hepatitis C Elimination Target Likely Out of Reachon April 17, 2024 at 11:36 am
Sole focus on screening and treatment may hinder experts from meeting the WHO's 2030 goal to eliminate hepatitis C virus (HCV).
- Viral hepatitis is a silent killer. It can’t be eliminated if it isn’t trackedon April 17, 2024 at 1:30 am
Before Covid emerged, viral hepatitis killed more people in the United States than all 60 other reportable infectious diseases combined.
via Bing News